NCT04892498UnknownPhase 2
A Prospective Multicenter Clinical Study of Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University16 sites in 1 country66 target enrollmentStarted: May 30, 2021Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 66
- Locations
- 16
- Primary Endpoint
- progression free survival，PFS
Study Overview
Brief Summary
This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years.
- •The enrolled patients meet the recurrence or metastasis of advanced solid malignant tumors, have a clear pathological diagnosis report or medical history, the guidelines do not clearly recommend standard treatment plans or cannot tolerate standard treatment plans, and have clear measurable metastatic lesions (>1cm);
- •No congestive heart failure, unstable angina, or unstable arrhythmia occurred in the past 6 months.
- •The patient's activity status score is 0-3 points based on the Eastern Cooperative Oncology Group (ECOG) scoring method, and the life expectancy assessment is ≥3 months.
- •No serious hematopoietic function, abnormal heart, lung, liver, kidney function and immune deficiency in the past.
- •One week before admission, the absolute value of T lymphocytes was ≥0.5 times the lower limit of normal, and neutrophils ≥1.0×109/L; AST and ALT were ≤3.0 times the upper limit of normal (for liver cancer/liver metastasis ≤5.0 times) Upper limit of normal); creatinine ≤3.0 times the upper limit of normal.
- •The patient have the ability to understand and voluntarily sign an informed consent form.
Exclusion Criteria
- •Pregnant or breastfeeding women.
- •Those with a history of other malignant diseases in the last 5 years, except for cured skin cancer and cervical carcinoma in situ.
- •If there is a history of uncontrolled epilepsy, central nervous system disease or mental disorder, the investigator's judgment of its clinical severity may hinder the signing of informed consent or affect the patient's compliance with medication.
- •Clinically serious (ie active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) grade II or more severe congestive heart failure, or severe arrhythmia requiring drug intervention, or recent A history of myocardial infarction within 12 months.
- •Those who need immunosuppressive therapy for organ transplantation.
- •A known major active infection, or the researcher's judgment has major blood, kidney, metabolism, gastrointestinal, endocrine function or metabolic disorders, or other serious uncontrolled accompanying diseases.
- •Those who are allergic to any research drug ingredients.
- •A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation, or those with other immune-related diseases that require long-term oral hormone therapy.
- •In the period of acute and chronic tuberculosis infection (T-spot test is positive, patients with suspected tuberculosis foci on chest X-ray).
- •Other situations that the researcher thinks are not suitable for inclusion in the group.
Arms & Interventions
RT+PD-1+GM-CSF+IL-2
Experimental
Intervention: Hypofractionated radiotherapy (Radiation)
RT+PD-1+GM-CSF+IL-2
Experimental
Intervention: PD-1 inhibitor (Drug)
RT+PD-1+GM-CSF+IL-2
Experimental
Intervention: GM-CSF (Drug)
RT+PD-1+GM-CSF+IL-2
Experimental
Intervention: IL-2 (Drug)
Outcomes
Primary Outcomes
progression free survival，PFS
Time Frame: Up to 3 years
Time from cycle 1, day 1 of treatment to disease progression or death due to any cause
Secondary Outcomes
- Overall response rate，ORR(Up to 3 years)
- Overall survival，OS(Up to 3 years)
- Disease control rate，DCR(Up to 3 years)
Investigators
Study Sites (16)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter StudyLeukemia, Lymphocytic, Acute, AdultNCT06649422Shandong University36
Recruiting
Phase 2
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLCNon-Small Cell Lung CancerNCT06379087Ji Yongling20
Suspended
Phase 2
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric AdenocarcinomaStomach AdenocarcinomaGastro-esophageal Junction CancerNCT06728657Fudan University68
Not yet recruiting
Unknown
Prospective Clinical Trial of Moderately Hypo-fractionated Intensity Modulated Radiation Therapy with Concurrent Administration of Daikenchuto for Prostate CancerProstate cancerJPRN-UMIN000053762Suita Tokushukai Hospital125
Completed
Not Applicable
To study the safety and efficacy of hypofractionated intensity modulated radiotherapy for patients with intermediate-risk prostate cancer.prostate cancerJPRN-UMIN000003218Department of Radiation Oncology, The Cancer Institute Hospita, the Japanese Fundation for Cancer Reseach30